WeedLife News Network

It’s important to really monitor your symptoms rather than trying to lock in a particular milligram that you think is beneficial to you.

I think sometimes we put a little too much work into really thinking about what the starting serving size is and making sure that we’re very exact with this. Remember that CBD and other cannabinoids are plants and oftentimes you’re administering to the point that you’re seeing a return on the administration, a result rather than looking at a particular number of milligrams in the serving size.

I just wanted to bring a couple of samples to show you from my own cabinet. I get so many samples of CBD given what I do for work, and here are three different products that I just pulled up quickly before I came to speak with you today.

If I were to tell you to choose a product and then take a half a dropper full as your first serving size, you can see how that’s a completely ridiculous thing to suggest because there is such a wide variability.

And in these different bottles there’s 4,000 milligrams in one bottle, just 500 milligrams in another and 1,000 milligrams in the next.

The state of Mississippi is set to roll out its medical marijuana program this summer.

The Mississippi State Department of Health, which is in charge of regulating the program, is currently building rules and a framework for the program. Those are scheduled to be released sometime in July, WJTV reported.

On August 15, licenses will be distributed and then the program will officially start.

Ken Newburger with the Mississippi Medical Marijuana Association told the news agency it was a smart move getting the health department to regulate the program.

“Because it’s a medical program and everything about it needs to be handled from a health medicine perspective, the State Department of Health was the best choice,” he said. “Most other states that have good, functioning medical marijuana programs chose the State Department of Health as their regulatory body. So that’s really why we felt like it was the right place.”

These days, you’d be hard pressed to find someone who isn’t using some type of cannabis product – either recreationally, therapeutically, or both… but have you ever wondered how everyone seems able to afford it?

Although many industries are struggling amid the ongoing pandemic, 2020 has been a record year for cannabis with prices and demand both at an all-time high. Everything from smokables to edibles, THC and CBD, dispensary and mail-order – everywhere you look there is a trending cannabis-based product.

What’s also holding firm, and increasing in many markets, is the prices for all the aforementioned items. In addition to cannabis being portrayed more favorably by the mainstream media, COVID-driven demand over the last year coupled with bottlenecks in supply has caused a surge in prices. And according to the U.S. Cannabis Spot Index Report, the average wholesale price per pound has reached its highest point in three years.

So, again that begs the question, how does it seem that everyone can afford these products so easily; considering high quality comes with an equally high price tag, and these products aren’t covered by insurance. We know they’re effective and safe, but are cannabis products an affordable alternative to prescription medication?

Benefits of medical cannabis

I believe this is an important staring point, because it’s the therapeutic aspect of cannabis that’s really behind this burgeoning demand. It has been used recreationally for decades, but it wasn’t until word got out about the safety profile and medical benefits that cannabis products really saw a surge in popularity.

In the United States, the most common use for medical cannabis is pain management. Although it isn’t really strong enough for very severe pain, post-surgical for example, it’s highly effective in controlling various forms of chronic pain that effects millions of Americans. Cannabis is frequently endorsed as a safer alternative to opiate medication, which are dangerously addictive and responsible for an alarming number of overdose deaths in the states.

Roughly five months. That is apparently when Mississippians can expect their newly approved medical marijuana program to begin to take shape.

Two months after voters in the Magnolia State approved a measure legalizing medical cannabis, officials in Mississippi are previewing what the program’s implementation will look like in the new year.

According to local television station WJTV, the next few months will see the Mississippi Department of Health examine best plans for implementation. By July, according to the station, the department “will outline the rules and framework”; on August 15 of this year, “licenses will be distributed, and then the program would officially start.”

WJTV reported that “all medical marijuana” in Mississippi will be regulated by the department, something Ken Newburger, the head of the Mississippi Medical Marijuana Association, told the station was an ideal arrangement.

“Because it’s a medical program and everything about it needs to be handled from a health medicine perspective, the State Department of Health was the best choice. Most other states that have good, functioning medical marijuana programs chose the State Department of Health as their regulatory body. So that’s really why we felt like it was the right place,” Newburger told WJTV.

More than half of people who use medical marijuana products to ease pain also experience clusters of multiple withdrawal symptoms when they're between uses, a new study finds.

And about 10% of the patients taking part in the study experienced worsening changes to their sleep, mood, mental state, energy and appetite over the next two years as they continued to use cannabis.

Many of them may not recognize that these symptoms come not from their underlying condition, but from their brain and body's reaction to the absence of substances in the cannabis products they're smoking, vaping, eating or applying to their skin, says the University of Michigan Addiction Center psychologist who led the study.

When someone experiences more than a few such symptoms, it's called cannabis withdrawal syndrome - and it can mean a higher risk of developing even more serious issues such as a cannabis use disorder.

In the new research published in the journal Addiction, a team from the U-M Medical School and the VA Ann Arbor Healthcare System reports findings from detailed surveys across two years of 527 Michigan residents. All were participating in the state's system to certify people with certain conditions for use of medical cannabis, and had non-cancer-related pain.

Results from a recently published study suggest U.S. consumers perceive CBD as more of an over-the-counter pain reliever and less like prescription opioid medicines.

The study was carried researchers Trey Malone and Brandon R. McFadden from the Department of Applied Economics and Statistics, University of Delaware.

Based on data from a national survey conducted in 2019 of 1,050 U.S. adult respondents, the study found more than half perceived CBD (cannabidiol), THC (tetrahydrocannabinol), hemp and marijuana as having medical use and also significantly less potential for abuse compared to commonly prescribed anti-anxiety and pain medications.

There was also a majority view that THC and marijuana had less potential for abuse than alcohol – this has become quite apparent in many states where the push for legalization for recreational use is gaining more support; and not just at a state level, but nationally as well.

Of the approximate 32% of respondents who had consumed CBD and/or THC, between 31% and 49% had used the cannabinoids as a replacement for other medications. Of those who replaced a conventional medication with CBD, 37% to 56% replaced an over-the-counter medication while only 21% to 23% replaced a prescription opioid.

In a recent study, Thomas M. Clark, Ph.D., head of a recent analysis, found that “the anticancer effects of cannabis outweigh the carcinogenic effects even in the airways and bladder, where carcinogen exposure is high.” 

Clark headed an August analysis directly on the issue of cannabis and cancer, supported by his sabbatical leave from Indiana University South Bend. At first, Clark had three hypotheses: cannabis increases cancer risk, the benefits and risks of using cannabis canceled out, or cannabis lowers cancer risk.  

At the first analysis of the data set, there was a slight association with cannabis and reduced cancer risk. However, by removing data that did not control for tobacco use, defined as data with a high risk for selection bias, and data at risk for performance bias, the association became medium to large.

Likewise, the data revealed a medium to large association with reduced cancer risk if data related to testicular cancer was removed. However, according to the analysis, “the hypothesis that cannabis use increases cancer risk is not supported by the available data.”  

Making Sense of the Complexity of Cancer Risk 

In the words of Clark, “decreased cancer risk in cannabis users should not be surprising, as cannabis and cannabinoids decrease obesity, inhibit chronic inflammation, reduce fasting insulin levels and insulin sensitivity, and have direct antitumor actions.”

These days the list of illnesses that cannabis medicines can be used for grows every day, with research studies being done left and right to test its efficacy against different symptoms and disorders. Most attention is focused on CBD because of its lack of psychoactive effects, while THC is often left out. However, it was found early on that THC is good for the eyes, and has been used to treat conditions like glaucoma for decades.

Bummed the holidays are over? We’ve got the perfect answer – keep shopping! Just because Christmas is over and New Year’s is nearly a thing of the past, doesn’t mean you have to stop giving gifts. We’ve still got all the best Delta-8 THC deals for everyone you know. So, don’t be sad that the holidays have come to an end…just keep the gifts flowing!

Medical cannabis back in the day

Before getting into the restart of medical cannabis in more recent decades, let’s go over some facts about the use of cannabis in medicine. Essentially, it’s been used in medicine for thousands of years, long before it was co-opted by Western medicine in the 1800’s, and then re-introduced once again after a period of enforced illegalization. It’s a part of two of the oldest medicinal traditions, Ayurvedic and Traditional Chinese Medicine, both of which have multiple applications for the use of cannabis to treat tons of different ailments. It has been used in many other lesser-known medical traditions as well.

Prior to it being scheduled as a narcotic by the Single Convention on Narcotic Substances which forced a global illegalization, cannabis was being used in all types of Western medicine applications. In fact, it was listed in the United States Pharmacopoeia for the first time in 1850, but dropped from there in 1937 following the Marijuana Tax act. Before the laws changed, it could be found in tons of products, for almost anything. Most people, of course, had no real understanding of this, but it does show that cannabis was being used very heavily in the world of medicine. Considering how many countries were forced into illegalizing the plant, this was not confined to just the US.

Cannabis has existed medicinally in essentially three stages. The first was everything up until the 1800’s when it was used in natural medicine traditions. The second stage was the original co-opting of the drug into Western medicine, and the third is the reintroduction back into Western medicine more recently.

David Spradin is the CEO of a California-based marijuana company called Perfect Union.

It has 14 marijuana stores between Los Angeles and Sacramento, six stores in New Mexico and has had stores in Oregon and Washington, says Rick McAuliffe, a Rhode Island lobbyist who now also serves as a director for Spradin’s new local affiliate: Perfect Union-RI.

The company and 27 other businesses all filed applications last month for a chance to run one of six new medical marijuana dispensaries planned for Rhode Island. 

While Spradin’s local venture incorporated just in November, the Californian has been around, buying up one marijuana cultivation operation, in Warwick, and purchasing a Providence site for a possible second — indicators of the interest some outside investors have with Rhode Island’s booming, multimillion-dollar marijuana industry.

Spradin’s Western stores sell in both the recreational and medical markets “and he thinks the opportunity in Rhode Island and the Northeast is very good,” says McAuliffe, particularly if Rhode Island joins several Northeast states and legalizes recreational use of the drug.

There’s still more to be done to improve patient access to medical cannabis in Western Australia says the director of a medical clinic in Perth’s western suburbs.

In November 2019, changes were made to Western Australia’s medical cannabis program to make patient access a little easier. Previously, patients would need a referral to a specialist from a GP in order to gain a prescription for cannabis medicines, but the change enabled GPs the ability to prescribe medicines where a patient is over the age of 16, isn’t drug dependent and doesn’t have a history of drug use.

The involvement of a specialist certainly appeared to discourage access. Between November 2016 and August 2019, only 876 approvals were granted. But further improvements are still required, particularly where medicinal cannabis is classified Schedule 8.

Speaking with radio station 6PR’s Gary Adshead last week, Director of St Francis Medical group David Cooper said doctors are still experiencing barriers within Western Australia’s health system.

“The doctors have to apply to state health if the treatment is a schedule eight or a controlled drug treatment,” said Mr. Cooper – and this was resulting in delays of up to 6 weeks for some patients.

In the whole ‘scare’ industry of marijuana, there’s a lot of weird, often illogical, mainly contradictory, and definitely silly stuff floating around. Often, when investigating further, it’s found that there’s a lot of talk, but not a lot of substantial information that this talk is based on. One of the more troubling theories, as far as I’m concerned, is that cannabis and schizophrenia are linked. Is this something that the standard marijuana smoker really has to worry about?

The holidays are over, but you still have shopping to do! We’ve got you covered with all the best Delta-8 THC deals right here!! Make your whole family happy, even after the holidays!!

What is cannabis?

Cannabis is a flowering plant of the Cannabaceae family. It’s generally split into three species: Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Some people consider them to be all the same species. Cannabis is known for its hemp fiber properties, its medicinal abilities, and its psychoactive effects, the latter of which have caused the plant to be unnecessarily scheduled in ways that keep it from public use.

Generally speaking, when referring to a plant that is less high in the psychoactive compound THC, the plant is considered hemp, and when it contains a large amount of THC, it’s considered marijuana. The cutoff in the US is .3% according to the last farm bill, but Europe makes the distinction at .2%. This distinction separates what can be used medicinally in many locations, especially where low-THC products are legal, but high-THC products are not.

What is schizophrenia?

Schizophrenia is a brain disorder which can include delusions and hallucinations for the sufferer. The condition is also associated with disorganized speech, general lack of motivation, and issues with proper thinking patterns. For many who suffer from it, it creates an inability to distinguish reality from fantasy. The symptoms of the disorder often take place in episodes of high intensity, intertwined with periods of normality. Approximately 1% of the population is estimated to have schizophrenia.  As of right now there is no cure for the disorder, and those with the condition are generally relegated to high doses of very strong medication. It is said that with medication, many with the affliction are able to keep their symptoms under control. There is no specific test that will give an answer as to whether a person has schizophrenia. Like many psychological disorders it is merely characterized by its symptoms, and diagnoses are given based on these symptoms.

With ever-climbing HPV-positive cancer rates, research on the effect CBD and THC has on the human papillomavirus can’t come soon enough.

Often called the common cold of the sexual world, the Centers for Disease Control states that HPV has infected over 79 million individuals worldwide. Both prevalent and highly contagious, HPV tends to thrive on porous skin located in the throat, anal cavity, cervix and tongue, making it extremely difficult to test and eradicate around the world.

Risk factors of HPV are a compromised immune system, smoking and poor diet and sleep. Thought to cause over 70% of cervical cancers, the World Health Organization states that HPV has more than 100 types and has one of the best known defenses: vaccination. 
For decades, researchers believed that marijuana played a role in HPV-related cervical cancer. However, a 2010 study, published in the U.S. National Library of Medicine, found that marijuana did not cause cervical cancer.

Understanding HPV’s infectivity

While once thought to only be contracted through sexual conduct, studies in the last two decades have showcased that HPV can live on surfaces. A 2002 study, published in the British Medical Journal found HPV DNA could live in a clinical environment, without skin-to-skin contact. A more recent and in-depth study, featured in Taylor & Francis Online, found that when comparing the bovine papillomavirus with the human papillomavirus, both showed a remarkable ability to retain a 50% infectivity at room temperature after 3 days. 

Additionally, in 2014, Penn State further researched earlier findings, discovering that unless a special method of cleaning instruments (autoclaving) or bleach was present, HPV was persistent on surfaces and was able to be transmitted. While still cited as a “sexually-transmitted infection,” HPV appears to be anything but. 

Bill Cobb uses medical marijuana to treat PTSD and chronic back pain.

“I’m a 50-year-old Black man who’s been a civil rights worker,” said Cobb, now a criminal justice activist in Philadelphia. “I smoke to have my brain slow down. But to be honest, I also smoke because I enjoy it.”

Alleviating his physical and mental pain is difficult when he feels another sting: His doctor-recommended medicine is not covered by insurance. He pays out of pocket — as much as $120 a week.

“It’s way too expensive,” Mr. Cobb said. “It’s ridiculous.”

Other marijuana users in Pennsylvania agree.

Patients in Ohio’s medical marijuana program say the information they find on legal marijuana dispensaries, cannabis products and prices come not from the state government or marijuana industry, but from a series of third-party websites run mostly by out-of-state companies.

Sites such as WeedMaps, Leafly and IHeartJane boast directories of places to buy medicinal cannabis. They aren’t all the same; Leafly, for example, offers reviews of specific products and strains of marijuana. IHeartJane lets users search for reviews of specific brands and patients can filter dispensaries to find those owned by veterans or members of minority groups. But all of the sites provide a clearinghouse for information on marijuana products.

The cannabis-focused media site OhioCannabis.com includes a list of Ohio dispensaries along with news and other information about the industry. The site also includes a directory of doctors who write marijuana recommendations and a ratings system for dispensaries.

“That's what I've done since the beginning is be a resource for patients,” OhioCannabis.com founder Johnny Lutz said.

The sites “serve a purpose since dispensary menus often do not provide details like THC/CBD content,” Mary Jane Borden, co-founder of the cannabis advocacy organization Ohio Rights Group, said in an email.

As time goes on, alternative plant medicine, such as cannabis, are slowly changing the way pain management is viewed and executed.

Did you know that in 2019, chronic pain impacted one-third of the U.S. population? This number continues to rise, and so does the consumption of various substances to help manage and/or combat pain.

Currently, different NSAIDs (non-steroidal anti-inflammatory drugs), acetaminophen, and opioids are used the most often for the treatment of pain. However, there’s no guarantee that these drugs will be fully effective in eliminating pain nor is there a guarantee that these drugs won’t cause any adverse side effects.

Nowadays, cannabis and its many cannabinoids are being pursued more because of their medicinal and therapeutic properties.Overall, though, alternative plant medicine is becoming a part of thousands of people’s routines and lifestyles for numerous reasons. Here are a few main reasons why.

Understanding Types of Pain and How to Treat It Properly

Oftentimes, when someone experiences pain, their primary mission is to eliminate it and use or consume a product to achieve relief. Before treating pain though, it’s important to understand the characteristics of the pain itself, the severity of it, and the nature of it. For example, is the pain acute or chronic? Is it neuropathic or inflammatory pain? Is the pain caused by an injury, illness, ailment, or a new medication? After understanding the type of pain, finding an appropriate treatment method is the next step.

Australia’s Neurotech International Limited (ASX: NTI) has reported final results of in-vitro studies indicate its DOLCE/NTI cannabis strains exhibit potent anti-inflammatory activity.

Neurotech acquired an exclusive worldwide license to utilise proprietary cannabis strains from Dolce Cann Global, which it hopes could potentially be used to treat neurological disorders including autism, epilepsy and ADHD.

Neurotech’s analysis of 80 cannabis samples from the Dolce Cann Global revealed varying amounts of  cannabinoids including CBDV, CBDA, CBGA, CBG, CBD, THCV, CBN, THC, d8-THC, CBC and THCA – some of the many cannabinoids found in cannabis. CBDA was found to be present in particularly high levels.

The company has been undertaking a series of in-vitro* studies to assess the neuroprotective, anti-inflammatory and neuro-modulatory activities of the strains. Neurotech says the final results indicate DOLCE/NTI strains examined have shown to significantly improve neuronal cell health, cell viability and have the potent ability to reduce inflammation.

“Preclinical studies suggest that these strains exhibit potent and unique properties when compared to CBD alone and warrant the further assessment of these strains in phase 1 clinical trials,” said Assoc. Prof. Fahey.

Medical marijuana sales in Arkansas have hit a significant milestone a little more than a year after the first dispensaries in the state began serving customers.

Local news outlets in the Natural State reported that medical cannabis sales in Arkansas have officially eclipsed $200 million, with patients purchasing more than 15 tons of product. 

The exact figures, according to local television stations KATV and 5NEWS: $200.7 million and 30,648 pounds of medical marijuana.

MMJ in AR

Voters in Arkansas approved a measure legalizing medical marijuana in 2016, but the first dispensary didn’t open until May of 2019. The law’s rollout faced impediments from state lawmakers and jurists in the nearly three years before the voters approved it at the ballot box and patients were able to be served, and has continued to face resistance. 

Lawmakers passed a measure last year, a month before sales began, significantly restricting the advertising of medical marijuana products. And in February, a county judge in Arkansas issued a freeze on the state’s ability to issue more licenses for dispensaries.

Medicinal cannabis could offer patients significant relief from intractable epilepsy, but cost and access barriers remain, a review has found.

Cannabis-based medicinal products (CBMPs) can offer patients significant relief from intractable epilepsy, according to evidence from a small number of patients.

In a review of 10 cases of severe childhood-onset epilepsy, Imperial’s Prof. David Nutt and Rayyan Zafar looked at the impact of combined CBD and THC-based products on the frequency of epileptic seizures.

They found carers reported a 97% reduction in monthly frequency of seizures when patients received whole plant extract cannabis treatments – not currently licenced in the UK – showing a clear benefit among this group. However, despite the clinical benefit, they cite the significant cost for their use and difficulty in accessing the treatments in the UK.

Zafar, a PhD candidate in the Department of Brain Sciences, said: “Patients and their families deserve better, so we implore policy makers, regulators and public health bodies to prioritise the health of these individuals and help them to access in the NHS medicines which are making a dramatic improvement to their lives.”